Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Gross Margin (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Gross Margin for 2 consecutive years, with 64.71% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 2724.0% to 64.71% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 64.3% through Dec 2025, down 833.0% year-over-year, with the annual reading at 61.54% for FY2025, 1116.0% down from the prior year.
  • Gross Margin hit 64.71% in Q4 2025 for Silence Therapeutics, up from 59.75% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 91.95% in Q4 2024 to a low of 322.12% in Q2 2024.